This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (71)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Statistics and Research Methods  • Journalology/ Peer Review/ Authorship  • Randomized Controlled Trial  • Alert me on articles by topic

Drummond Rennie, MD

JAMA. 1999;282:1766-1768.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Meta-analysis, done properly, is a systematic effort to search for and winnow out all the best evidence and show how well a given intervention works. It is crucially dependent on the identification of all available data from clinical trials. In 1989, Gøtzsche,¹ who was performing a meta-analysis of 244 trials of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis, drew attention to a practice that seemed to subvert the normal process of publication as well as of meta-analysis. Excluding abstracts, letters, and brief versions, Gøtzsche found 44 multiple publications of 31 of the clinical trials, 20 trials published twice, 10 three times, and 1 trial 5 times, with the overall proportion of multiple publications being at least 18%. The fact that the data had been published elsewhere was not noted in 32 of the 44 articles. Indeed, in about half of them, the first author and number of authors . . . [Full Text of this Article]

Author Affiliation: Dr Rennie is Deputy Editor (West), JAMA. He is also affiliated with the San Francisco Cochrane Center, University of California.

RELATED ARTICLES

Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen and Peter C. Gøtzsche
JAMA. 1999;282(18):1752-1759.
ABSTRACT | FULL TEXT  

Appendix: Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen and Peter C. Gøtzsche
JAMA. 1999;282(18):1756-1757.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?
Chan et al.
JCO 2008;26:1511-1518.
ABSTRACT | FULL TEXT  

Evidence of publication bias in reporting acute stroke clinical trials.
Liebeskind et al.
Neurology 2006;67:973-979.
ABSTRACT | FULL TEXT  

Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.
Ridker and Torres
JAMA 2006;295:2270-2274.
ABSTRACT | FULL TEXT  

Psychiatric Training Program Engagement With the Pharmaceutical Industry: An Educational Issue, Not Strictly an Ethical One
Mohl
Acad. Psychiatry 2005;29:215-221.
ABSTRACT | FULL TEXT  

Total elbow arthroplasty: A SYSTEMATIC REVIEW OF THE LITERATURE IN THE ENGLISH LANGUAGE UNTIL THE END OF 2003
Little et al.
J Bone Joint Surg Br 2005;87-B:437-444.
FULL TEXT  

Trial Registration: A Great Idea Switches From Ignored to Irresistible
Rennie
JAMA 2004;292:1359-1362.
FULL TEXT  

EVIDENCE-BASED DENTISTRY
Toal
Journal of the American Dental Association 2003;134:1430-1430.
FULL TEXT  

Registering Clinical Trials
Dickersin and Rennie
JAMA 2003;290:516-523.
ABSTRACT | FULL TEXT  

Getting it right: industry sponsorship and medical research
Baird
CMAJ 2003;168:1267-1269.
FULL TEXT  

Consensus and contention regarding redundant publications in clinical research: cross-sectional survey of editors and authors
Yank and Barnes
J. Med. Ethics 2003;29:109-114.
ABSTRACT | FULL TEXT  

Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman et al.
JAMA 2003;289:454-465.
ABSTRACT | FULL TEXT  

Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility
Manheimer and Anderson
BMJ 2002;325:528-531.
ABSTRACT | FULL TEXT  

Scientific Data from Clinical Trials: Investigators' Responsibilities and Rights
Ann. Surg. Oncol. 2002;9:421-422.
FULL TEXT  

Potential solutions to the problem of conducting systematic reviews of new health technologies
Moher and Schachter
CMAJ 2002;166:1674-1675.
FULL TEXT  

Scientific Data From Clinical Trials: Investigators' Responsibilities and Rights
Arch Surg 2002;137:639-640.
FULL TEXT  

The dilemmas posed by new and fashionable treatments
Healy
Adv. Psychiatr. Treat. 2001;7:322-327.
FULL TEXT  

CONSORT Revised--Improving the Reporting of Randomized Trials
Rennie
JAMA 2001;285:2006-2007.
FULL TEXT  

Moving From Compliance to Conscience: Why We Can and Should Improve on the Ethics of Clinical Research
Kahn and Mastroianni
Arch Intern Med 2001;161:925-928.
FULL TEXT  

Challenges for publishing medical and public health research in the 2000s
Emmelin
Scand J Public Health 2001;29:1-4.
 

Defining and Describing Benefit Appropriately in Clinical Trials
King
J Law Med Ethics 2000;28:332-343.
 

Better Access to Information about Clinical Trials
McCray
ANN INTERN MED 2000;133:609-614.
ABSTRACT | FULL TEXT  

Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
Meibach et al.
Neurology 2000;55:1069-1069.
FULL TEXT  

The Contributions of Authors
Rennie et al.
JAMA 2000;284:89-91.
FULL TEXT  

Improving the Conduct and Reporting of Clinical Trials
Bernhardt et al.
JAMA 2000;283:2787-2790.
FULL TEXT  

Pharmacoeconomic Analyses: Making Them Transparent, Making Them Credible
Rennie and Luft
JAMA 2000;283:2158-2160.
FULL TEXT  

Scientific harassment by pharmaceutical companies: time to stop
Hailey
CMAJ 2000;162:212-213.
FULL TEXT